Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Shares Outstanding (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 15 years of Shares Outstanding data on record, last reported at $1.5 billion in Q3 2025.

  • For Q3 2025, Shares Outstanding rose 18.04% year-over-year to $1.5 billion; the TTM value through Sep 2025 reached $1.5 billion, up 18.04%, while the annual FY2024 figure was $1.3 billion, 13.03% up from the prior year.
  • Shares Outstanding reached $1.5 billion in Q3 2025 per NWBO's latest filing, up from $1.5 billion in the prior quarter.
  • Across five years, Shares Outstanding topped out at $1.5 billion in Q3 2025 and bottomed at $857230.0 in Q2 2021.
  • Average Shares Outstanding over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2023.
  • Peak YoY movement for Shares Outstanding: surged 131081.49% in 2021, then grew 2.78% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $948.4 million in 2021, then grew by 12.65% to $1.1 billion in 2022, then grew by 10.02% to $1.2 billion in 2023, then grew by 13.03% to $1.3 billion in 2024, then grew by 14.28% to $1.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $1.5 billion in Q3 2025, $1.5 billion in Q2 2025, and $1.4 billion in Q1 2025.